Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company based in Dublin, Ireland. They are focused on developing a product called LUMRYZ, which is being tested in Phase 3 clinical trial. LUMRYZ contains sodium oxybate and is intended to treat excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was previously known as Flamel Technologies SA before changing its name to Avadel Pharmaceuticals plc (NASDAQ:AVDL) in January 2017. It was founded in 2015 and operates primarily in the United States. Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares have returned over 500% value to investors over the past 12 months. Craig-Hallum, on June30, increased its price target on Avadel Pharmaceuticals plc (NASDAQ:AVDL) from $16 to $18.